Ge, Weizhi published the artcileSynthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents, SDS of cas: 16909-09-4, the publication is European Journal of Medicinal Chemistry (2019), 445-469, database is CAplus and MEDLINE.
Triple-neg. breast cancer (TNBC) is the most aggressive cancers with a high recurrence rate and rapidly acquired drug resistance among various breast cancer subtypes. There is no specific drug for treatment of TNBC. Discovery of therapeutic agents with unique modes of actions is urgently needed. In this study, a series of seventy parthenolide derivatives was designed, synthesized, and evaluated for their anti-TNBC activities. Compound I exhibited the most potent activity against different breast cancer cells with IC50 values ranging from 0.20 ¦ÌM to 0.27 ¦ÌM, which demonstrated 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 ¦ÌM. It is worth to note that I was more active than the pos. control drug ADR. Moreover, compound I could induce apoptosis of SUM-159 cells through mitochondria pathway and cause G1 phase arrest of SUM-159 cells. These findings indicate that compound I deserves further studies as a lead compound for ultimate discovery of effective anti-TNBC drug.
European Journal of Medicinal Chemistry published new progress about 16909-09-4. 16909-09-4 belongs to catalysis-chemistry, auxiliary class Alkenyl,Carboxylic acid,Benzene,Ether, name is (E)-3-(2,4-Dimethoxyphenyl)acrylic acid, and the molecular formula is C11H12O4, SDS of cas: 16909-09-4.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia